Wim van den Brink

40.4k total citations · 2 hit papers
586 papers, 25.9k citations indexed

About

Wim van den Brink is a scholar working on Clinical Psychology, Epidemiology and Psychiatry and Mental health. According to data from OpenAlex, Wim van den Brink has authored 586 papers receiving a total of 25.9k indexed citations (citations by other indexed papers that have themselves been cited), including 177 papers in Clinical Psychology, 173 papers in Epidemiology and 163 papers in Psychiatry and Mental health. Recurrent topics in Wim van den Brink's work include Substance Abuse Treatment and Outcomes (154 papers), Neurotransmitter Receptor Influence on Behavior (131 papers) and Schizophrenia research and treatment (86 papers). Wim van den Brink is often cited by papers focused on Substance Abuse Treatment and Outcomes (154 papers), Neurotransmitter Receptor Influence on Behavior (131 papers) and Schizophrenia research and treatment (86 papers). Wim van den Brink collaborates with scholars based in Netherlands, United States and Germany. Wim van den Brink's co-authors include Anna E. Goudriaan, Dick J. Veltman, Jan van Amsterdam, Maarten W.J. Koeter, Jaap Oosterlaan, Jan Booij, Vincent M. Hendriks, Roel Verheul, Ingmar H. A. Franken and Edwin de Beurs and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Nature Neuroscience.

In The Last Decade

Wim van den Brink

569 papers receiving 24.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gabapentin, opioids, and the risk of opioid-related death: A population-based nested case–control study

2017 361 citations Wim van den Brink et al. profile →
Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations

2017 301 citations Benedikt Fischer, Cayley Russell et al. American Journal of Public Health profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wim van den Brink Netherlands	85	9.2k	5.6k	5.4k	5.1k	4.8k	586	25.9k
Thomas R. Kosten United States	77	4.3k 0.5×	7.3k 1.3×	5.1k 0.9×	3.9k 0.8×	3.9k 0.8×	567	22.9k
Kathleen T. Brady United States	84	9.6k 1.0×	4.2k 0.8×	5.2k 1.0×	3.8k 0.8×	2.7k 0.6×	478	23.7k
Kathleen M. Carroll United States	86	7.9k 0.9×	3.4k 0.6×	8.9k 1.7×	3.9k 0.8×	2.6k 0.6×	364	23.8k
Charles P. O’Brien United States	77	3.9k 0.4×	9.3k 1.7×	7.8k 1.5×	3.1k 0.6×	3.3k 0.7×	353	24.5k
Warren K. Bickel United States	85	5.6k 0.6×	4.9k 0.9×	6.2k 1.2×	3.0k 0.6×	2.0k 0.4×	501	30.2k
Harriet de Wit United States	82	5.9k 0.6×	12.9k 2.3×	3.5k 0.7×	2.8k 0.6×	4.4k 0.9×	427	28.4k
Dan I. Lubman Australia	67	5.7k 0.6×	2.5k 0.4×	4.1k 0.8×	3.1k 0.6×	2.9k 0.6×	540	16.6k
Bruce J. Rounsaville United States	87	10.2k 1.1×	4.3k 0.8×	9.5k 1.8×	5.2k 1.0×	2.5k 0.5×	314	25.4k
Henry R. Kranzler United States	88	5.1k 0.6×	8.2k 1.5×	10.8k 2.0×	3.3k 0.7×	3.2k 0.7×	610	28.2k
Michael T. Lynskey United States	91	9.8k 1.1×	2.1k 0.4×	10.7k 2.0×	3.1k 0.6×	8.0k 1.7×	380	27.1k

Countries citing papers authored by Wim van den Brink

Since Specialization

Citations

This map shows the geographic impact of Wim van den Brink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wim van den Brink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wim van den Brink more than expected).

Fields of papers citing papers by Wim van den Brink

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wim van den Brink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wim van den Brink. The network helps show where Wim van den Brink may publish in the future.

Co-authorship network of co-authors of Wim van den Brink

This figure shows the co-authorship network connecting the top 25 collaborators of Wim van den Brink. A scholar is included among the top collaborators of Wim van den Brink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wim van den Brink. Wim van den Brink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Amsterdam, Jan van & Wim van den Brink. (2025). Designer benzodiazepines: Availability, motives, and fatalities. A systematic narrative review of human studies. Drug and Alcohol Dependence. 272. 112708–112708. 1 indexed citations

Ritter, Alison, James Bell, John Strang, et al.. (2025). Bridging the evidence and the politics: Implementation trial of supervised injectable opioid treatment (SIOT) in Australia. International Journal of Drug Policy. 138. 104749–104749.

Lin, Bochao, Jentien M. Vermeulen, Koen Bolhuis, et al.. (2023). Associations between genetic liabilities to smoking behavior and schizophrenia symptoms in patients with a psychotic disorder, their siblings and healthy controls. Psychiatry Research. 323. 115143–115143.

Crunelle, Cleo L., Frieda Matthys, Lies Gremeaux, et al.. (2023). Patient Reported Outcome and Experience Measures (PROMs and PREMs) in substance use disorder treatment services: A scoping review. Drug and Alcohol Dependence. 253. 111017–111017. 18 indexed citations

Vorspan, Florence, Cleo L. Crunelle, Wim van den Brink, et al.. (2022). Consensus International sur le dépistage, le diagnostic et le traitement des patients avec troubles de l’usage de substances en cas de comorbidité avec un trouble du déficit de l’attention avec ou sans hyperactivité. Annales de Toxicologie Analytique. 34(2). 55–67. 1 indexed citations

Knottnerus, J. André, et al.. (2022). Cannabis policy in The Netherlands: Rationale and design of an experiment with a controlled legal (‘closed’) cannabis supply chain. Health Policy. 129. 104699–104699. 7 indexed citations

Amsterdam, Jan van, Gjalt-Jorn Peters, E. J. M. Pennings, et al.. (2021). Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis. Journal of Psychopharmacology. 35(5). 537–546. 3 indexed citations

Glind, Geurt van de, Arvid Skutle, Sharlene Kaye, et al.. (2020). The International Collaboration on ADHD and Substance Abuse (ICASA): Mission, Results, and Future Activities. European Addiction Research. 26(4-5). 173–178. 17 indexed citations

Fischer, Benedikt, Cayley Russell, Pamela Sabioni, et al.. (2017). Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health. 107(8). e1–e12. 301 indexed citations breakdown →

10.

Kaag, Anne Marije, et al.. (2017). The effect of N-acetylcysteine on brain glutamate and gamma-aminobutyric acid concentrations and on smoking cessation: A randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology. 31(10). 1377–1379. 19 indexed citations

11.

Koenders, Laura, Janna Cousijn, Wim van den Brink, et al.. (2016). Grey Matter Changes Associated with Heavy Cannabis Use: A Longitudinal sMRI Study. PLoS ONE. 11(5). e0152482–e0152482. 57 indexed citations

12.

Goossens, Peter J. J., et al.. (2015). Burden and Expressed Emotion of Caregivers in Cases of Adult Substance Use Disorder with and Without Attention Deficit/Hyperactivity Disorder or Autism Spectrum Disorder. International Journal of Mental Health and Addiction. 14(1). 49–63. 11 indexed citations

13.

Amsterdam, Jan van, Lawrence D. Phillips, Graeme Henderson, et al.. (2015). Ranking the harm of non-medically used prescription opioids in the UK. Regulatory Toxicology and Pharmacology. 73(3). 999–1004. 16 indexed citations

14.

Sjoerds, Zsuzsika, Judy Luigjes, Wim van den Brink, Damiaan Denys, & Murat Yücel. (2014). The Role of Habits and Motivation in Human Drug Addiction: A Reflection. Frontiers in Psychiatry. 5. 8–8. 24 indexed citations

15.

Pol, Peggy van der, Nienke Liebregts, Tibor M. Brunt, et al.. (2014). Cross‐sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction. 109(7). 1101–1109. 92 indexed citations

16.

Boschloo, Lynn, Nicole Vogelzangs, Wim van den Brink, et al.. (2012). Alcohol use disorders and the course of depressive and anxiety disorders. The British Journal of Psychiatry. 200(6). 476–484. 86 indexed citations

17.

Dom, Geert, Bieke De Wilde, Wouter Hulstijn, Wim van den Brink, & Bernard Sabbe. (2006). BEHAVIOURAL ASPECTS OF IMPULSIVITY IN ALCOHOLICS WITH AND WITHOUT A CLUSTER-B PERSONALITY DISORDER. Alcohol and Alcoholism. 41(4). 412–420. 65 indexed citations

18.

Brink, Wim van den, et al.. (2006). Comorbid psychopathology in adolescents and young adults treated for substance use disorders. European Child & Adolescent Psychiatry. 15(6). 319–328. 104 indexed citations

19.

Brink, Wim van den, S. Tuinier, W.M.A. Verhoeven, et al.. (1999). NEU volume 11 issue 1 Cover and Front matter. Acta Neuropsychiatrica. 11(1). f1–f4. 1 indexed citations

20.

Brink, Wim van den, et al.. (1991). Mental health intervention programs in primary care: their scientific basis. Journal of Affective Disorders. 21(4). 273–284. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact